Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,81,2088,DB01065,Melatonin
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,50,2089,DB01065,Melatonin
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,26,2090,DB01065,Melatonin
,27000757,t max,"Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established.",Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27000757/),min,30-45,3355,DB01065,Melatonin
,27000757,t ½elimination,"Currently, a t max value of 30-45 min and a t ½elimination of 45 min are well established.",Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27000757/),min,45,3356,DB01065,Melatonin
,21110748,solubility,"The selected compounds are lipophilic in nature, exhibiting aqueous solubility ranging from 40 to 200 microg/mL.",3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110748/),[μg] / [ml],40 to 200,4437,DB01065,Melatonin
,21110748,half-life,"These compounds were, however, subjected to rapid cytochrome P450-mediated degradation in rat and human liver microsomes with in vitro half-life of 9.5-31.9 min in rat and 5.5-66.7 min in human, which were much shorter than that of melatonin (approximately 73 min).",3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110748/),min,9.5-31.9,4438,DB01065,Melatonin
,21110748,half-life,"These compounds were, however, subjected to rapid cytochrome P450-mediated degradation in rat and human liver microsomes with in vitro half-life of 9.5-31.9 min in rat and 5.5-66.7 min in human, which were much shorter than that of melatonin (approximately 73 min).",3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110748/),min,5.5-66.7,4439,DB01065,Melatonin
,21110748,half-life,"These compounds were, however, subjected to rapid cytochrome P450-mediated degradation in rat and human liver microsomes with in vitro half-life of 9.5-31.9 min in rat and 5.5-66.7 min in human, which were much shorter than that of melatonin (approximately 73 min).",3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110748/),min,73,4440,DB01065,Melatonin
,31004517,time-to-peak blood concentration,"In both groups that received ST-OS and SLN-OS, the median time-to-peak blood concentration was 0.5 hours; however, the area under the curve (AUC) after administration of SLN-OS was significantly higher than after ST-OS (157386 [65732-193653] vs 44441 [22319-90705] pg/mL*hours, P = 0.048).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),h,0.5,7291,DB01065,Melatonin
,31004517,area under the curve (AUC),"In both groups that received ST-OS and SLN-OS, the median time-to-peak blood concentration was 0.5 hours; however, the area under the curve (AUC) after administration of SLN-OS was significantly higher than after ST-OS (157386 [65732-193653] vs 44441 [22319-90705] pg/mL*hours, P = 0.048).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),[pg] / [h·ml],157386,7292,DB01065,Melatonin
,31004517,area under the curve (AUC),"In both groups that received ST-OS and SLN-OS, the median time-to-peak blood concentration was 0.5 hours; however, the area under the curve (AUC) after administration of SLN-OS was significantly higher than after ST-OS (157386 [65732-193653] vs 44441 [22319-90705] pg/mL*hours, P = 0.048).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),[pg] / [h·ml],44441,7293,DB01065,Melatonin
,31004517,time-to-peak blood concentration,"μE-TD presented a delayed time-to-peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344-14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132-1583] pg/mL).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),h,4,7294,DB01065,Melatonin
,31004517,bioavailability (,"μE-TD presented a delayed time-to-peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344-14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132-1583] pg/mL).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),[pg] / [h·ml],3142,7295,DB01065,Melatonin
,31004517,AUC,"μE-TD presented a delayed time-to-peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344-14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132-1583] pg/mL).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),[pg] / [h·ml],3142,7296,DB01065,Melatonin
,31004517,peak concentration,"μE-TD presented a delayed time-to-peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344-14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132-1583] pg/mL).",Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31004517/),[pg] / [ml],388,7297,DB01065,Melatonin
,18330178,Tmax,"Compared to MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC and mean half life of elimination was significantly higher (respectively 169944.7 +/- 64954.4 pg/ml x hour vs. 85148.4 +/- 50642.6 pg/ml x hour, p = 0.018 and 93.1 +/- 37.1 min vs. 48.2 +/- 8.9 min, p = 0.009).",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),[pg] / [h·ml],169944.7,10277,DB01065,Melatonin
,18330178,AUC,"Compared to MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC and mean half life of elimination was significantly higher (respectively 169944.7 +/- 64954.4 pg/ml x hour vs. 85148.4 +/- 50642.6 pg/ml x hour, p = 0.018 and 93.1 +/- 37.1 min vs. 48.2 +/- 8.9 min, p = 0.009).",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),[pg] / [h·ml],169944.7,10278,DB01065,Melatonin
,18330178,half life of elimination,"Compared to MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC and mean half life of elimination was significantly higher (respectively 169944.7 +/- 64954.4 pg/ml x hour vs. 85148.4 +/- 50642.6 pg/ml x hour, p = 0.018 and 93.1 +/- 37.1 min vs. 48.2 +/- 8.9 min, p = 0.009).",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),min,93.1,10279,DB01065,Melatonin
,18330178,half life of elimination,"Compared to MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC and mean half life of elimination was significantly higher (respectively 169944.7 +/- 64954.4 pg/ml x hour vs. 85148.4 +/- 50642.6 pg/ml x hour, p = 0.018 and 93.1 +/- 37.1 min vs. 48.2 +/- 8.9 min, p = 0.009).",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),min,48.2,10280,DB01065,Melatonin
,18330178,half life of absorption,"MT absorption and elimination after MT-SLN-TD demonstrated to be slow (mean half life of absorption: 5.3 +/- 1.3 hours; mean half life of elimination: 24.6 +/- 12.0 hours), so MT plasma levels above 50 pg/ml were maintained for at least 24 hours.",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),h,5.3,10281,DB01065,Melatonin
,18330178,half life of elimination,"MT absorption and elimination after MT-SLN-TD demonstrated to be slow (mean half life of absorption: 5.3 +/- 1.3 hours; mean half life of elimination: 24.6 +/- 12.0 hours), so MT plasma levels above 50 pg/ml were maintained for at least 24 hours.",Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330178/),h,24.6,10282,DB01065,Melatonin
,12661062,brain:plasma ratio,"BMS-214778 distributed from the plasma to brain in the rat (mean +/- SD brain:plasma ratio of 0.9 +/- 0.1, N = 3).","Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12661062/),,0.9,13887,DB01065,Melatonin
,4021725,peak values,Elevated melatonin concentrations were observed with peak values of 435 nmol/l in serum and 241 nmol/l in saliva at 60 min.,"Oral administration and distribution of melatonin in human serum, saliva and urine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4021725/),[nM] / [l],435,24218,DB01065,Melatonin
,4021725,peak values,Elevated melatonin concentrations were observed with peak values of 435 nmol/l in serum and 241 nmol/l in saliva at 60 min.,"Oral administration and distribution of melatonin in human serum, saliva and urine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4021725/),[nM] / [l],241,24219,DB01065,Melatonin
,4021725,half-lives,"The half-lives for serum and saliva melatonin were 41 and 38 min, respectively.","Oral administration and distribution of melatonin in human serum, saliva and urine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4021725/),min,41,24220,DB01065,Melatonin
,4021725,half-lives,"The half-lives for serum and saliva melatonin were 41 and 38 min, respectively.","Oral administration and distribution of melatonin in human serum, saliva and urine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4021725/),min,38,24221,DB01065,Melatonin
,29194416,half-life,"The half-life of melatonin in plasma ranged from 7.98 to 10.94 h, and the area under the curve (AUC) from 10.48 to 118.17 µg·mL-1·h-1.",Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194416/),h,7.98 to 10.94,24347,DB01065,Melatonin
,29194416,area under the curve (AUC),"The half-life of melatonin in plasma ranged from 7.98 to 10.94 h, and the area under the curve (AUC) from 10.48 to 118.17 µg·mL-1·h-1.",Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194416/),[μg] / [h·ml],10.48 to 118.17,24348,DB01065,Melatonin
,27865856,peak time (Tmax),"Compared with raw MLT, MLT-SiO2-HP55 prolonged peak time (Tmax) from 15min to 30min and increased peak concentration (Cmax) from 168.86ng/mL to 383.71ng/mL.","Melatonin-loaded silica coated with hydroxypropyl methylcellulose phthalate for enhanced oral bioavailability: Preparation, and in vitro-in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865856/),min,15,27799,DB01065,Melatonin
,27865856,peak time (Tmax),"Compared with raw MLT, MLT-SiO2-HP55 prolonged peak time (Tmax) from 15min to 30min and increased peak concentration (Cmax) from 168.86ng/mL to 383.71ng/mL.","Melatonin-loaded silica coated with hydroxypropyl methylcellulose phthalate for enhanced oral bioavailability: Preparation, and in vitro-in vivo evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865856/),min,30,27800,DB01065,Melatonin
,27865856,peak concentration (Cmax),"Compared with raw MLT, MLT-SiO2-HP55 prolonged peak time (Tmax) from 15min to 30min and increased peak concentration (Cmax) from 168.86ng/mL to 383.71ng/mL.","Melatonin-loaded silica coated with hydroxypropyl methylcellulose phthalate for enhanced oral bioavailability: Preparation, and in vitro-in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865856/),[ng] / [ml],168.86,27801,DB01065,Melatonin
,27865856,peak concentration (Cmax),"Compared with raw MLT, MLT-SiO2-HP55 prolonged peak time (Tmax) from 15min to 30min and increased peak concentration (Cmax) from 168.86ng/mL to 383.71ng/mL.","Melatonin-loaded silica coated with hydroxypropyl methylcellulose phthalate for enhanced oral bioavailability: Preparation, and in vitro-in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865856/),[ng] / [ml],383.71,27802,DB01065,Melatonin
,18464272,K,"Population typical values (CV%) were: A(B); 103 ng (103%), K(OUT); 0.255 h(-1) (57.8%), AMP; 34.9 (108%), WID; 2.3 h (20.9%), T(0); 14.8 h (4.4%).",A population pharmacokinetic turnover and surge-function model for describing melatonin biological rhythm in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18464272/),,34.9,30206,DB01065,Melatonin
,10332069,bioavailability,"The bioavailability for +GC was 94% (S.D.+/-29%, n=4), whereas the bioavailability for -GC was 55% (S.D.+/-17%, n=6).",Intranasal absorption of melatonin in vivo bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),%,94,33259,DB01065,Melatonin
,10332069,bioavailability,"The bioavailability for +GC was 94% (S.D.+/-29%, n=4), whereas the bioavailability for -GC was 55% (S.D.+/-17%, n=6).",Intranasal absorption of melatonin in vivo bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),%,55,33260,DB01065,Melatonin
,10332069,serum half-life,"The pharmacokinetics of melatonin could be described by a one-compartment model, and the serum half-life was about 13 min.",Intranasal absorption of melatonin in vivo bioavailability study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),min,13,33261,DB01065,Melatonin
,10332069,tmax,"The absorption rate for both formulations was very fast (tmax=5 min) and Cmax mean was 493+/-290 ng/ml (n=4) and 249+/-125 ng/ml (n=6) for +GC and -GC, respectively.",Intranasal absorption of melatonin in vivo bioavailability study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),min,5,33262,DB01065,Melatonin
,10332069,Cmax,"The absorption rate for both formulations was very fast (tmax=5 min) and Cmax mean was 493+/-290 ng/ml (n=4) and 249+/-125 ng/ml (n=6) for +GC and -GC, respectively.",Intranasal absorption of melatonin in vivo bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),[ng] / [ml],493,33263,DB01065,Melatonin
,10332069,Cmax,"The absorption rate for both formulations was very fast (tmax=5 min) and Cmax mean was 493+/-290 ng/ml (n=4) and 249+/-125 ng/ml (n=6) for +GC and -GC, respectively.",Intranasal absorption of melatonin in vivo bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332069/),[ng] / [ml],249,33264,DB01065,Melatonin
,22642804,solubility,IS0042 was considerably lipophilic with a modest aqueous solubility of 27.3 µg/mL.,"Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),[μg] / [ml],27.3,34094,DB01065,Melatonin
,22642804,half-life,"IS0042 underwent metabolism in rat intestinal and liver microsomes with an in vitro half-life of 367.5 ± 36.6 and 17.5 ± 2.7 min, respectively.","Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),min,367.5,34095,DB01065,Melatonin
,22642804,half-life,"IS0042 underwent metabolism in rat intestinal and liver microsomes with an in vitro half-life of 367.5 ± 36.6 and 17.5 ± 2.7 min, respectively.","Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),min,17.5,34096,DB01065,Melatonin
,22642804,clearance,"IS0042 showed moderate clearance (0.73-1.02 L/h/kg), large volume of distribution (1.76-3.16 L/kg) and long elimination half-life (3.11-6.04 h) after intravenous administration.","Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),[l] / [h·kg],0.73-1.02,34097,DB01065,Melatonin
,22642804,volume of distribution,"IS0042 showed moderate clearance (0.73-1.02 L/h/kg), large volume of distribution (1.76-3.16 L/kg) and long elimination half-life (3.11-6.04 h) after intravenous administration.","Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),[l] / [kg],1.76-3.16,34098,DB01065,Melatonin
,22642804,elimination half-life,"IS0042 showed moderate clearance (0.73-1.02 L/h/kg), large volume of distribution (1.76-3.16 L/kg) and long elimination half-life (3.11-6.04 h) after intravenous administration.","Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),h,3.11-6.04,34099,DB01065,Melatonin
,22642804,absolute oral bioavailability,The absolute oral bioavailability of IS0042 was relatively low (9.8-18.6%).,"Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642804/),%,9.8-18.6,34100,DB01065,Melatonin
,2054148,half lives,"5-MT showed a one compartment kinetic profile in the plasma with half lives of 14.8 min after 2 weeks, 15 min after 5 weeks and 19.1 min after 8 weeks.","Plasma concentrations of 5-methoxytryptamine, 5-methoxytryptophol and melatonin after 5-methoxytryptamine administration of golden hamsters: physiological implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054148/),min,14.8,36783,DB01065,Melatonin
,2054148,half lives,"5-MT showed a one compartment kinetic profile in the plasma with half lives of 14.8 min after 2 weeks, 15 min after 5 weeks and 19.1 min after 8 weeks.","Plasma concentrations of 5-methoxytryptamine, 5-methoxytryptophol and melatonin after 5-methoxytryptamine administration of golden hamsters: physiological implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054148/),min,15,36784,DB01065,Melatonin
,2054148,half lives,"5-MT showed a one compartment kinetic profile in the plasma with half lives of 14.8 min after 2 weeks, 15 min after 5 weeks and 19.1 min after 8 weeks.","Plasma concentrations of 5-methoxytryptamine, 5-methoxytryptophol and melatonin after 5-methoxytryptamine administration of golden hamsters: physiological implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054148/),min,19.1,36785,DB01065,Melatonin
,23432339,half-life,Infants receiving melatonin at 0.1 μg kg(-1) h(-1) for 2 h showed a median half-life of 15.82 h and median maximum plasma concentration of 203.3 pg ml(-1) .,Pharmacokinetics of melatonin in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23432339/),h,15.82,37456,DB01065,Melatonin
,23432339,maximum plasma concentration,Infants receiving melatonin at 0.1 μg kg(-1) h(-1) for 2 h showed a median half-life of 15.82 h and median maximum plasma concentration of 203.3 pg ml(-1) .,Pharmacokinetics of melatonin in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23432339/),[pg] / [ml],203.3,37457,DB01065,Melatonin
,23432339,clearance,"On population pharmacokinetics, clearance was 0.045 l h(-1) , volume of distribution 1.098 l and elimination half-life 16.91 h with gender (P = 0.047) and race (P < 0.0001) as significant covariates.",Pharmacokinetics of melatonin in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23432339/),[l] / [h],0.045,37458,DB01065,Melatonin
,23432339,volume of distribution,"On population pharmacokinetics, clearance was 0.045 l h(-1) , volume of distribution 1.098 l and elimination half-life 16.91 h with gender (P = 0.047) and race (P < 0.0001) as significant covariates.",Pharmacokinetics of melatonin in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23432339/),l,1.098,37459,DB01065,Melatonin
,23432339,elimination half-life,"On population pharmacokinetics, clearance was 0.045 l h(-1) , volume of distribution 1.098 l and elimination half-life 16.91 h with gender (P = 0.047) and race (P < 0.0001) as significant covariates.",Pharmacokinetics of melatonin in preterm infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23432339/),h,16.91,37460,DB01065,Melatonin
,23170926,days open,"Significant differences in days open between groups (means 123 ± 71.9 and 103 ± 43, respectively, for C and M; p = 0.02) were registered.",Melatonin treatment at dry-off improves reproductive performance postpartum in high-producing dairy cows under heat stress conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23170926/),,123,41121,DB01065,Melatonin
,23170926,days open,"Significant differences in days open between groups (means 123 ± 71.9 and 103 ± 43, respectively, for C and M; p = 0.02) were registered.",Melatonin treatment at dry-off improves reproductive performance postpartum in high-producing dairy cows under heat stress conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23170926/),,103,41122,DB01065,Melatonin
,25851638,absolute bioavailability,"Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here.","Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851638/),%,38,47044,DB01065,Melatonin
,9787493,elimination half-life,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),min,27,49241,DB01065,Melatonin
,9787493,elimination half-life,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),min,27,49242,DB01065,Melatonin
,9787493,mean residence time,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),min,24,49243,DB01065,Melatonin
,9787493,mean residence time,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),min,18,49244,DB01065,Melatonin
,9787493,steady state distribution volume,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),[l] / [kg],1.0,49245,DB01065,Melatonin
,9787493,steady state distribution volume,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),[1] / [kg],0.6,49246,DB01065,Melatonin
,9787493,plasma clearance,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),[l] / [kg·min],0.044,49247,DB01065,Melatonin
,9787493,plasma clearance,"The values (mean +/- SD) for the cows and the goats were: elimination half-life 27 +/- 4 min and 27 +/- 1 min, mean residence time 24 +/- 4 min and 18 +/- 4 min, steady state distribution volume 1.0 +/- 0.3 l/kg and 0.6 +/- 0.1 1/kg (p < 0.05), and plasma clearance 0.044 +/- 0.004 l/kg/min and 0.035 +/- 0.011 l/kg/min, respectively.",Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9787493/),[l] / [kg·min],0.035,49248,DB01065,Melatonin
,24602553,peak time (acrophase),"However, in postmenopausal women the melatonin peak time (acrophase) was delayed by 2.4h (2 h 21 min) on average after 6 months with HT vs. placebo (p<0.05).","The effect of hormone therapy on serum melatonin concentrations in premenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602553/),h,2.4,55821,DB01065,Melatonin
,26184078,Cmax,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[pg] / [ml],"221,500.0",64058,DB01065,Melatonin
,26184078,Cmax,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[pg] / [ml],"1,251,500.0",64059,DB01065,Melatonin
,26184078,t1/2,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),min,42.3,64060,DB01065,Melatonin
,26184078,t1/2,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),min,46.2,64061,DB01065,Melatonin
,26184078,Vd,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[l] / [kg],1.6,64062,DB01065,Melatonin
,26184078,Vd,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[l] / [kg],2.0,64063,DB01065,Melatonin
,26184078,CL,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[l] / [kg·min],0.0253,64064,DB01065,Melatonin
,26184078,CL,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[l] / [kg·min],0.0300,64065,DB01065,Melatonin
,26184078,AUC0- ∞,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),[min·pg] / [ml],"8,997,633.0",64066,DB01065,Melatonin
,26184078,AUC0- ∞,"Median (IQR) Cmax after the bolus injections of 10 mg and 100 mg of melatonin were 221,500.0 (185,637.5-326,175.0) pg/mL and 1,251,500.0 (864,375.0-1,770,500.0) pg/mL, respectively; mean (SD) t1/2 was 42.3 (5.6) minutes and 46.2 (6.2) minutes; mean (SD) Vd was 1.6 (0.9) L/kg and 2.0 (0.8) L/kg; mean (SD) CL was 0.0253 (0.0096) L/min · kg and 0.0300 (0.0120) L/min · kg; and median (IQR) AUC0- ∞ , 8,997,633.0 (6,071,696.2-11,602,811.9) pg · min/mL and 54,685,979.4 (36,028,638.6-105,779,612.0) pg · min/mL.",Pharmacokinetics of high-dose intravenous melatonin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26184078/),,"54,685,979.4",64067,DB01065,Melatonin
,20070489,half-absorption time,"Following enteral administration, pharmacological levels were already reached in 5 min, with a serum peak after 16 min (half-absorption time: 3 min 17 s).",Pharmacokinetics of orally administered melatonin in critically ill patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20070489/),min,3,68057,DB01065,Melatonin
,20070489,half-absorption time,"Following enteral administration, pharmacological levels were already reached in 5 min, with a serum peak after 16 min (half-absorption time: 3 min 17 s).",Pharmacokinetics of orally administered melatonin in critically ill patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20070489/),s,17,68058,DB01065,Melatonin
,20070489,maximum serum level,The maximum serum level observed was 11040 pg/mL and the disappearance rate indicated a half-elimination time of 1 hr 34 min.,Pharmacokinetics of orally administered melatonin in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20070489/),[pg] / [ml],11040,68059,DB01065,Melatonin
,20070489,half-elimination time,The maximum serum level observed was 11040 pg/mL and the disappearance rate indicated a half-elimination time of 1 hr 34 min.,Pharmacokinetics of orally administered melatonin in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20070489/),h,1,68060,DB01065,Melatonin
,20070489,half-elimination time,The maximum serum level observed was 11040 pg/mL and the disappearance rate indicated a half-elimination time of 1 hr 34 min.,Pharmacokinetics of orally administered melatonin in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20070489/),min,34,68061,DB01065,Melatonin
,8626852,terminal elimination rate constant,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),1/[h],1.08,70279,DB01065,Melatonin
,8626852,terminal elimination rate constant,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),1/[h],0.89,70280,DB01065,Melatonin
,8626852,elimination half-life,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),h,0.67,70281,DB01065,Melatonin
,8626852,elimination half-life,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),h,0.79,70282,DB01065,Melatonin
,8626852,area under the concentration-time curve,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),[pg] / [h·ml)],250.9,70283,DB01065,Melatonin
,8626852,area under the concentration-time curve,"However, developmental differences were significant between prepubertal children and adults for terminal elimination rate constant (1.08 +/- 0.25 vs. 0.89 +/- 0.11 h-1), elimination half-life (0.67 +/- 0.12 vs. 0.79 +/- 0.10 h), and area under the concentration-time curve (250.9 +/- 91.8 vs. 376.9 +/- 154.3 (pg/mL).h, respectively).",Pharmacokinetics of melatonin in human sexual maturation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),[pg] / [h·ml)],376.9,70284,DB01065,Melatonin
,8626852,terminal elimination rate constant,Results based on salivary melatonin showed significant differences between prepubertal children and adults for the terminal elimination rate constant (1.90 +/- 0.95 vs. 1.06 +/- 0.28 h-1).,Pharmacokinetics of melatonin in human sexual maturation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),1/[h],1.90,70285,DB01065,Melatonin
,8626852,terminal elimination rate constant,Results based on salivary melatonin showed significant differences between prepubertal children and adults for the terminal elimination rate constant (1.90 +/- 0.95 vs. 1.06 +/- 0.28 h-1).,Pharmacokinetics of melatonin in human sexual maturation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626852/),1/[h],1.06,70286,DB01065,Melatonin
,7937522,Plasma protein binding,Plasma protein binding of S 20098 ranged from 75 to 95%.,Microdialysis: an alternative for in vitro and in vivo protein binding studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937522/),%,75 to 95,72709,DB01065,Melatonin
,7937522,unbound fraction,"Microdialysis was also performed in vivo in freely moving rats under steady-state conditions, yielding similar unbound fraction values (26.0 +/- 0.9%) to those obtained using microdialysis probes in rat plasma in vitro (24.4 +/- 1.6%).",Microdialysis: an alternative for in vitro and in vivo protein binding studies. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937522/),%,26.0,72710,DB01065,Melatonin
,7937522,unbound fraction,"Microdialysis was also performed in vivo in freely moving rats under steady-state conditions, yielding similar unbound fraction values (26.0 +/- 0.9%) to those obtained using microdialysis probes in rat plasma in vitro (24.4 +/- 1.6%).",Microdialysis: an alternative for in vitro and in vivo protein binding studies. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937522/),%,24.4,72711,DB01065,Melatonin
,22348451,time to maximum level,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.3,80194,DB01065,Melatonin
,22348451,time to maximum level,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.5,80195,DB01065,Melatonin
,22348451,elimination half-life,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.8,80196,DB01065,Melatonin
,22348451,elimination half-life,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,2.1,80197,DB01065,Melatonin
,22348451,apparent total clearance,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[l] / [h],379,80198,DB01065,Melatonin
,22348451,apparent total clearance,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[l] / [h],478,80199,DB01065,Melatonin
,22348451,maximum concentration,"The maximum concentration was 405 ±93pg/mL for the low-dose arm and 3999±700pg/mL for the high-dose arm, both of which are substantially higher than physiologic melatonin levels for this age group.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[pg] / [ml],405,80200,DB01065,Melatonin
,22348451,maximum concentration,"The maximum concentration was 405 ±93pg/mL for the low-dose arm and 3999±700pg/mL for the high-dose arm, both of which are substantially higher than physiologic melatonin levels for this age group.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[pg] / [ml],3999,80201,DB01065,Melatonin
,15180337,T(max),Melatonin is quickly absorbed in plasma (T(max) = 2.5 min) and shows a delayed uptake into CSF (T(max) = 15 min) after nasal administration.,Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15180337/),min,2.5,81767,DB01065,Melatonin
,15180337,T(max),Melatonin is quickly absorbed in plasma (T(max) = 2.5 min) and shows a delayed uptake into CSF (T(max) = 15 min) after nasal administration.,Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15180337/),min,15,81768,DB01065,Melatonin
,15180337,AUC(CSF)/AUC(plasma) ratio,"The AUC(CSF)/AUC(plasma) ratio after nasal delivery (32.7 +/- 6.3%) does not differ from the one after intravenous injection (46.0 +/- 10.4%), which indicates that melatonin enters the CSF via the blood circulation across the blood-brain barrier.",Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15180337/),%,32.7,81769,DB01065,Melatonin
,15180337,AUC(CSF)/AUC(plasma) ratio,"The AUC(CSF)/AUC(plasma) ratio after nasal delivery (32.7 +/- 6.3%) does not differ from the one after intravenous injection (46.0 +/- 10.4%), which indicates that melatonin enters the CSF via the blood circulation across the blood-brain barrier.",Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15180337/),%,46.0,81770,DB01065,Melatonin
,9699222,peak concentrations,"Mean peak concentrations of MT in serum were reached between 0.5 h and 0.75 h (Cmax[1] pmol/ml): 20.7 (A), 16.4 (B), 9.7 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],20.7,82409,DB01065,Melatonin
,9699222,peak concentrations,"Mean peak concentrations of MT in serum were reached between 0.5 h and 0.75 h (Cmax[1] pmol/ml): 20.7 (A), 16.4 (B), 9.7 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],16.4,82410,DB01065,Melatonin
,9699222,Cmax,"Mean peak concentrations of MT in serum were reached between 0.5 h and 0.75 h (Cmax[1] pmol/ml): 20.7 (A), 16.4 (B), 9.7 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],20.7,82411,DB01065,Melatonin
,9699222,Cmax,"Mean peak concentrations of MT in serum were reached between 0.5 h and 0.75 h (Cmax[1] pmol/ml): 20.7 (A), 16.4 (B), 9.7 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],16.4,82412,DB01065,Melatonin
,9699222,Cmax,"Mean peak concentrations of MT in serum were reached between 0.5 h and 0.75 h (Cmax[1] pmol/ml): 20.7 (A), 16.4 (B), 9.7 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],9.7,82413,DB01065,Melatonin
,9699222,Cmax[2],"The capsules B and C released a second MT pulse after about 3.5 h with Cmax[2] of 13.0 and 17.5 pmol/ml, respectively.",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],13.0,82414,DB01065,Melatonin
,9699222,Cmax[2],"The capsules B and C released a second MT pulse after about 3.5 h with Cmax[2] of 13.0 and 17.5 pmol/ml, respectively.",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [ml],17.5,82415,DB01065,Melatonin
,9699222,AUC0-infinity,"Dose proportionality for the MT preparations studied was calculated by determining the AUC0-infinity (pmol/ml.h): 18.4 (A), 36.1 (B), 42.4 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [h·ml],18.4,82416,DB01065,Melatonin
,9699222,AUC0-infinity,"Dose proportionality for the MT preparations studied was calculated by determining the AUC0-infinity (pmol/ml.h): 18.4 (A), 36.1 (B), 42.4 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [h·ml],36.1,82417,DB01065,Melatonin
,9699222,AUC0-infinity,"Dose proportionality for the MT preparations studied was calculated by determining the AUC0-infinity (pmol/ml.h): 18.4 (A), 36.1 (B), 42.4 (C).",Evaluation of an oral pulsatile delivery system for melatonin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),[pM] / [h·ml],42.4,82418,DB01065,Melatonin
,9699222,terminal serum half-lives,The terminal serum half-lives of MT ranged between 0.64 and 0.84 h.,Evaluation of an oral pulsatile delivery system for melatonin in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699222/),h,0.64 and 0.84,82419,DB01065,Melatonin
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB01065,Melatonin
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB01065,Melatonin
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB01065,Melatonin
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB01065,Melatonin
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB01065,Melatonin
,16513163,transdermal flux,"Skin permeation profile of melatonin through elastic liposomal formulations was observed and the investigations revealed an enhanced transdermal flux (51.2+/-2.21 microg/cm(2)/h), decreased lag time (1.1h) and an optimum permeability coefficient (15.06+/-0.52 cm/h) for melatonin.",Transdermal delivery of a pineal hormone: melatonin via elastic liposomes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513163/),[μg] / [cm(2)·h],51.2,86222,DB01065,Melatonin
,16513163,lag time,"Skin permeation profile of melatonin through elastic liposomal formulations was observed and the investigations revealed an enhanced transdermal flux (51.2+/-2.21 microg/cm(2)/h), decreased lag time (1.1h) and an optimum permeability coefficient (15.06+/-0.52 cm/h) for melatonin.",Transdermal delivery of a pineal hormone: melatonin via elastic liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513163/),h,1.1,86223,DB01065,Melatonin
,16513163,permeability coefficient,"Skin permeation profile of melatonin through elastic liposomal formulations was observed and the investigations revealed an enhanced transdermal flux (51.2+/-2.21 microg/cm(2)/h), decreased lag time (1.1h) and an optimum permeability coefficient (15.06+/-0.52 cm/h) for melatonin.",Transdermal delivery of a pineal hormone: melatonin via elastic liposomes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513163/),[cm] / [h],15.06,86224,DB01065,Melatonin
,30734962,peak plasma concentration,The peak plasma concentration reached 0.25 µg/mL.,Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30734962/),[μg] / [ml],0.25,93173,DB01065,Melatonin
,30734962,area under the curve in 24 hours,The area under the curve in 24 hours was 4.35 µg/mL*h.,Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30734962/),[μg] / [h·ml],4.35,93174,DB01065,Melatonin
,11360039,extraction recovery,The mean extraction recovery was 59% for melatonin and 42% for 6-hydroxymelatonin.,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),%,59,100999,DB01065,Melatonin
,11360039,extraction recovery,The mean extraction recovery was 59% for melatonin and 42% for 6-hydroxymelatonin.,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),%,42,101000,DB01065,Melatonin
,11360039,limit of detection,The limit of detection was approximately 2 ng/mL for 6-hydroxymelatonin (signal/noise ratio = 4) and less than 2 ng/mL for melatonin (signal/noise ratio at 2 ng/mL = 10).,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),[ng] / [ml],2,101001,DB01065,Melatonin
,11360039,signal/noise ratio,The limit of detection was approximately 2 ng/mL for 6-hydroxymelatonin (signal/noise ratio = 4) and less than 2 ng/mL for melatonin (signal/noise ratio at 2 ng/mL = 10).,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),,4,101002,DB01065,Melatonin
less,11360039,signal/noise ratio,The limit of detection was approximately 2 ng/mL for 6-hydroxymelatonin (signal/noise ratio = 4) and less than 2 ng/mL for melatonin (signal/noise ratio at 2 ng/mL = 10).,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),[ng] / [ml],2,101003,DB01065,Melatonin
,11360039,signal/noise ratio,The limit of detection was approximately 2 ng/mL for 6-hydroxymelatonin (signal/noise ratio = 4) and less than 2 ng/mL for melatonin (signal/noise ratio at 2 ng/mL = 10).,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),[ng] / [ml],2,101004,DB01065,Melatonin
,11360039,signal/noise ratio,The limit of detection was approximately 2 ng/mL for 6-hydroxymelatonin (signal/noise ratio = 4) and less than 2 ng/mL for melatonin (signal/noise ratio at 2 ng/mL = 10).,Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360039/),[ng] / [ml],10,101005,DB01065,Melatonin
,32937627,time to maximal concentration,"We documented a mean (SD) time to maximal concentration of 51 (29) min for intravesical, 24 (20) min for rectal, 21 (8) h for transdermal, and 147 (56) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,51,106357,DB01065,Melatonin
,32937627,time to maximal concentration,"We documented a mean (SD) time to maximal concentration of 51 (29) min for intravesical, 24 (20) min for rectal, 21 (8) h for transdermal, and 147 (56) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,24,106358,DB01065,Melatonin
,32937627,time to maximal concentration,"We documented a mean (SD) time to maximal concentration of 51 (29) min for intravesical, 24 (20) min for rectal, 21 (8) h for transdermal, and 147 (56) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),h,21,106359,DB01065,Melatonin
,32937627,time to maximal concentration,"We documented a mean (SD) time to maximal concentration of 51 (29) min for intravesical, 24 (20) min for rectal, 21 (8) h for transdermal, and 147 (56) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,147,106360,DB01065,Melatonin
,32937627,elimination half-life,"The mean (SD) elimination half-life was 47 (6) min for intravenous, 58 (7) min for intravesical, 60 (18) min for rectal, 14.6 (11.1) h for transdermal, and 129 (17) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,47,106361,DB01065,Melatonin
,32937627,elimination half-life,"The mean (SD) elimination half-life was 47 (6) min for intravenous, 58 (7) min for intravesical, 60 (18) min for rectal, 14.6 (11.1) h for transdermal, and 129 (17) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,58,106362,DB01065,Melatonin
,32937627,elimination half-life,"The mean (SD) elimination half-life was 47 (6) min for intravenous, 58 (7) min for intravesical, 60 (18) min for rectal, 14.6 (11.1) h for transdermal, and 129 (17) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,60,106363,DB01065,Melatonin
,32937627,elimination half-life,"The mean (SD) elimination half-life was 47 (6) min for intravenous, 58 (7) min for intravesical, 60 (18) min for rectal, 14.6 (11.1) h for transdermal, and 129 (17) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),h,14.6,106364,DB01065,Melatonin
,32937627,elimination half-life,"The mean (SD) elimination half-life was 47 (6) min for intravenous, 58 (7) min for intravesical, 60 (18) min for rectal, 14.6 (11.1) h for transdermal, and 129 (17) min for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),min,129,106365,DB01065,Melatonin
,32937627,bioavailability,"The mean (SD) bioavailability was 3.6 (1.9)% for intravesical, 36.0 (28.6)% for rectal, 10.0 (5.7)% for transdermal, and 97.8 (31.7)% for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),%,3.6,106366,DB01065,Melatonin
,32937627,bioavailability,"The mean (SD) bioavailability was 3.6 (1.9)% for intravesical, 36.0 (28.6)% for rectal, 10.0 (5.7)% for transdermal, and 97.8 (31.7)% for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),%,36.0,106367,DB01065,Melatonin
,32937627,bioavailability,"The mean (SD) bioavailability was 3.6 (1.9)% for intravesical, 36.0 (28.6)% for rectal, 10.0 (5.7)% for transdermal, and 97.8 (31.7)% for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),%,10.0,106368,DB01065,Melatonin
,32937627,bioavailability,"The mean (SD) bioavailability was 3.6 (1.9)% for intravesical, 36.0 (28.6)% for rectal, 10.0 (5.7)% for transdermal, and 97.8 (31.7)% for vaginal administration.","Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32937627/),%,97.8,106369,DB01065,Melatonin
,26893170,t 1/2 absorption,Mean (SD) t 1/2 absorption of oral melatonin was 6.0 (3.1) min.,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),min,6.0,113659,DB01065,Melatonin
,26893170,t max,Mean t max was 40.8 (17.8) min with a median (IQR) C max of 3550.5 (2500.5-8057.5) pg ml(-1).,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),min,40.8,113660,DB01065,Melatonin
,26893170,C max,Mean t max was 40.8 (17.8) min with a median (IQR) C max of 3550.5 (2500.5-8057.5) pg ml(-1).,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),[pg] / [ml],3550.5,113661,DB01065,Melatonin
,26893170,t 1/2 elimination,Mean t 1/2 elimination was 53.7 (7.0) min.,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),min,53.7,113662,DB01065,Melatonin
,26893170,absolute bioavailability,Median absolute bioavailability was 2.5 (1.7-4.7) %.,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),%,2.5,113663,DB01065,Melatonin
,26893170,C max,"Median C max after short iv infusion of melatonin was 389,875.0 (174,775.0-440,362.5) pg ml(-1).",Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),[pg] / [ml],"389,875.0",113664,DB01065,Melatonin
,26893170,t 1/2 elimination,"Mean t 1/2 elimination was 39.4 (3.6) min, mean V d 1.2 (0.6) l kg(-1) and mean CL 0.0218 (0.0102) l min(-1) kg(-1).",Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),min,39.4,113665,DB01065,Melatonin
,26893170,V d,"Mean t 1/2 elimination was 39.4 (3.6) min, mean V d 1.2 (0.6) l kg(-1) and mean CL 0.0218 (0.0102) l min(-1) kg(-1).",Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),[l] / [kg],1.2,113666,DB01065,Melatonin
,26893170,CL,"Mean t 1/2 elimination was 39.4 (3.6) min, mean V d 1.2 (0.6) l kg(-1) and mean CL 0.0218 (0.0102) l min(-1) kg(-1).",Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),[l] / [kg·min],0.0218,113667,DB01065,Melatonin
,26893170,Bioavailability,Bioavailability of oral melatonin was only 3 %.,Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26893170/),%,3,113668,DB01065,Melatonin
less,26445481,oral bioavailability,"Although melatonin exhibits oncostatic properties such as antiproliferative effects, the oral bioavailability of this hormone is less than 20%.",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),%,20,118008,DB01065,Melatonin
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,40.0,118009,DB01065,Melatonin
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,54.1,118010,DB01065,Melatonin
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,81.8,118011,DB01065,Melatonin
,26445481,viability rate,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,92.7,118012,DB01065,Melatonin
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,27.0,118013,DB01065,Melatonin
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,21.5,118014,DB01065,Melatonin
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,10.1,118015,DB01065,Melatonin
,26445481,spontaneous,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,9.1,118016,DB01065,Melatonin
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,51.2,118017,DB01065,Melatonin
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,36.0,118018,DB01065,Melatonin
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,4.9,118019,DB01065,Melatonin
,26445481,apoptosis index,"MCF-7 cells incubated with melatonin adsorbed to PEG microspheres showed a lower viability rate (40.0 ± 8.3 with melatonin adsorbed to PEG microspheres compared to 54.1 ± 7.3 with melatonin; 81.8 ± 12.5 with PEG microsphere and 92.7 ± 4.1 with medium), increased spontaneous intracellular Ca2+ release (27.0 ± 8.6 with melatonin adsorbed to PEG microspheres compared to 21.5 ± 13.4 with melatonin; 10.1 ± 5.4 with PEG microsphere and 9.1 ± 5.6 with medium) and increased apoptosis index (51.2 ± 2.7 with melatonin adsorbed to PEG microspheres compared to 36.0 ± 2.1 with melatonin; 4.9 ± 0.5 with PEG microsphere and 3.1 ± 0.6 with medium).",The Effect of Melatonin Adsorbed to Polyethylene Glycol Microspheres on the Survival of MCF-7 Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445481/),,3.1,118020,DB01065,Melatonin
,15036995,circulating half-life,"The calculated circulating half-life (mean +/- S.E.M) of oral melatonin was 45.4+/-3.5 min, and the elimination rate constant (k(10)) was 55.2+/-4.2 min(-1).",Influence of oral melatonin on natural and gonadotropin-induced ovarian function in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15036995/),min,45.4,120714,DB01065,Melatonin
,15036995,elimination rate constant (k(10)),"The calculated circulating half-life (mean +/- S.E.M) of oral melatonin was 45.4+/-3.5 min, and the elimination rate constant (k(10)) was 55.2+/-4.2 min(-1).",Influence of oral melatonin on natural and gonadotropin-induced ovarian function in the domestic cat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15036995/),1/[min],55.2,120715,DB01065,Melatonin
,33682410,Ki,"Further optimization of these derivatives based on their metabolic stability in human hepatic microsomes revealed that (S)-3b ((S)-N-[2-(2-methyl-7,8-dihydro-6H-indeno[5,4-d][1,3]oxazol-8-yl)ethyl]acetamide) was a potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes.",Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33682410/),nM,0.031,122140,DB01065,Melatonin
,33682410,Ki,"Further optimization of these derivatives based on their metabolic stability in human hepatic microsomes revealed that (S)-3b ((S)-N-[2-(2-methyl-7,8-dihydro-6H-indeno[5,4-d][1,3]oxazol-8-yl)ethyl]acetamide) was a potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes.",Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33682410/),nM,0.070,122141,DB01065,Melatonin
,10841265,Brain distribution space,Brain distribution space of 3-OMG increased from 2 min to 20 min reaching equilibrium from that time onwards at a value of 0.14 ml x g(-1).,Uptake of 3-O-methyl-D-[U-14C]glucose into brain of rainbow trout: possible effects of melatonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841265/),min,2,122175,DB01065,Melatonin
,10841265,Brain distribution space,Brain distribution space of 3-OMG increased from 2 min to 20 min reaching equilibrium from that time onwards at a value of 0.14 ml x g(-1).,Uptake of 3-O-methyl-D-[U-14C]glucose into brain of rainbow trout: possible effects of melatonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841265/),min,20,122176,DB01065,Melatonin
,10841265,Brain distribution space,Brain distribution space of 3-OMG increased from 2 min to 20 min reaching equilibrium from that time onwards at a value of 0.14 ml x g(-1).,Uptake of 3-O-methyl-D-[U-14C]glucose into brain of rainbow trout: possible effects of melatonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841265/),[ml] / [g],0.14,122177,DB01065,Melatonin
,10841265,clearance of glucose from blood to brain (k1),"The unidirectional clearance of glucose from blood to brain (k1) and the fractional clearance of glucose from brain to blood (k2) were estimated to be 0.093 m x min(-1) x g(-1), and 0.867 min(-1), respectively.",Uptake of 3-O-methyl-D-[U-14C]glucose into brain of rainbow trout: possible effects of melatonin. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841265/),[m] / [g·min],0.093,122178,DB01065,Melatonin
,10841265,fractional clearance of glucose from brain to blood (k2),"The unidirectional clearance of glucose from blood to brain (k1) and the fractional clearance of glucose from brain to blood (k2) were estimated to be 0.093 m x min(-1) x g(-1), and 0.867 min(-1), respectively.",Uptake of 3-O-methyl-D-[U-14C]glucose into brain of rainbow trout: possible effects of melatonin. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841265/),1/[min],0.867,122179,DB01065,Melatonin
,30300675,peak plasma melatonin levels,"Mean ± SD peak plasma melatonin levels after the first infusion were 0.0014 ± 0.0012 mg/l in the HT + V group, 3.97 ± 1.53 mg/l in the HT + Mel-5 group and 16.8 ± 8.3 mg/l in the HT + Mel-15 group.",Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300675/),[mg] / [l],0.0014,122827,DB01065,Melatonin
,30300675,peak plasma melatonin levels,"Mean ± SD peak plasma melatonin levels after the first infusion were 0.0014 ± 0.0012 mg/l in the HT + V group, 3.97 ± 1.53 mg/l in the HT + Mel-5 group and 16.8 ± 8.3 mg/l in the HT + Mel-15 group.",Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300675/),[mg] / [l],3.97,122828,DB01065,Melatonin
,30300675,peak plasma melatonin levels,"Mean ± SD peak plasma melatonin levels after the first infusion were 0.0014 ± 0.0012 mg/l in the HT + V group, 3.97 ± 1.53 mg/l in the HT + Mel-5 group and 16.8 ± 8.3 mg/l in the HT + Mel-15 group.",Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300675/),[mg] / [l],16.8,122829,DB01065,Melatonin
,25658956,total clearance,"The total clearance and volume of distribution of tasimelteon, from the IV treatment, were 505 mL per minute and 42.7 L, respectively.",Absolute Bioavailability of Tasimelteon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25658956/),[ml] / [min],505,123801,DB01065,Melatonin
,25658956,volume of distribution,"The total clearance and volume of distribution of tasimelteon, from the IV treatment, were 505 mL per minute and 42.7 L, respectively.",Absolute Bioavailability of Tasimelteon. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25658956/),l,42.7,123802,DB01065,Melatonin
,25658956,absolute bioavailability,"Based on the statistical comparison of dose-corrected area under the curve to infinity, the absolute bioavailability was 38%, with a 90% confidence interval of 27%-54%.",Absolute Bioavailability of Tasimelteon. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25658956/),%,38,123803,DB01065,Melatonin
,9611160,production rate,"Highly significant differences between groups in nocturnal melatonin production rate were observed (L: 25.7 +/- 2.8 vs. H: 63.1 +/- 8.9 microg . kg-1 . h-1, P < 0.01).","Genetic variability in melatonin concentrations in ewes originates in its synthesis, not in its catabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9611160/),[μg] / [h·kg],25.7,123863,DB01065,Melatonin
,9611160,production rate,"Highly significant differences between groups in nocturnal melatonin production rate were observed (L: 25.7 +/- 2.8 vs. H: 63.1 +/- 8.9 microg . kg-1 . h-1, P < 0.01).","Genetic variability in melatonin concentrations in ewes originates in its synthesis, not in its catabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9611160/),[μg] / [h·kg],63.1,123864,DB01065,Melatonin
,3994899,elimination half-lives,"Gelatine capsules and the corn oil preparation gave reproducibly timed peak plasma concentrations, 30 to 60 min after ingestion regardless of nutritional status, and plasma melatonin remained at or above endogenous night-time levels for 3-4 h with mean elimination half-lives of 0.54 to 0.67 h.",Plasma concentrations of melatonin in man following oral absorption of different preparations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994899/),h,0.54 to 0.67,126609,DB01065,Melatonin
,15019067,entrapment ratio,The entrapment ratio of melatonin in the microspheres was 11.0% and particle sizes ranged from 30 to 60 microm.,Intranasal administration of melatonin starch microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019067/),%,11.0,126619,DB01065,Melatonin
,15019067,T(max),"The absorption rate was rapid (T(max) min), and the absolute bioavailability was high, 84.07%.",Intranasal administration of melatonin starch microspheres. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019067/),,min,126620,DB01065,Melatonin
,15019067,absolute bioavailability,"The absorption rate was rapid (T(max) min), and the absolute bioavailability was high, 84.07%.",Intranasal administration of melatonin starch microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019067/),%,84.07,126621,DB01065,Melatonin
,10085470,Cmax1,"Mean peak concentrations of MLT in serum (pmol/ml) were reached between 0.5 h and 0.75 h: Cmax1 20.7 (A), 16.4 (B), 9.7 (C).",A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085470/),[pM] / [ml],20.7,129696,DB01065,Melatonin
,10085470,Cmax1,"Mean peak concentrations of MLT in serum (pmol/ml) were reached between 0.5 h and 0.75 h: Cmax1 20.7 (A), 16.4 (B), 9.7 (C).",A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085470/),,16.4,129697,DB01065,Melatonin
,10085470,Cmax1,"Mean peak concentrations of MLT in serum (pmol/ml) were reached between 0.5 h and 0.75 h: Cmax1 20.7 (A), 16.4 (B), 9.7 (C).",A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085470/),,9.7,129698,DB01065,Melatonin
,10085470,Cmax2,"Capsules B and C released a second MLT pulse after about 3.5 h with Cmax2 of 13.0 and 17.5 pmol/ml, respectively.",A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085470/),[pM] / [ml],13.0,129699,DB01065,Melatonin
,10085470,Cmax2,"Capsules B and C released a second MLT pulse after about 3.5 h with Cmax2 of 13.0 and 17.5 pmol/ml, respectively.",A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10085470/),[pM] / [ml],17.5,129700,DB01065,Melatonin
,8891318,peak concentrations,"Treatment with 2.5 or 0.25 mg/kg dosages of melatonin in saline vehicle induced peak concentrations of melatonin in AH-POA microdialysates within 20 min of injection (165 +/- 34 and 18 +/- 8 pg/20 min, respectively).",Pharmacokinetics of extracellular melatonin in Siberian hamster forebrain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891318/),-1·pg,165,152960,DB01065,Melatonin
,8891318,peak concentrations,"Treatment with 2.5 or 0.25 mg/kg dosages of melatonin in saline vehicle induced peak concentrations of melatonin in AH-POA microdialysates within 20 min of injection (165 +/- 34 and 18 +/- 8 pg/20 min, respectively).",Pharmacokinetics of extracellular melatonin in Siberian hamster forebrain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891318/),min,18,152961,DB01065,Melatonin
less,8891318,half-life of the absorbed melatonin (t 1/2 elimination),"For the 2.5 and 0.25 mg/kg dosages, the half-life of the absorbed melatonin (t 1/2 elimination) was less than 20 min, and the concentrations fell to baseline within 60 min after injection.",Pharmacokinetics of extracellular melatonin in Siberian hamster forebrain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891318/),min,20,152962,DB01065,Melatonin
,26351927,clearance,"The patients administered melatonin had a mean clearance, volume of distribution and absorption rate constant of melatonin was 55.2 L/h, 767 L and 0.76 h-1, respectively.",Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26351927/),[l] / [h],55.2,154088,DB01065,Melatonin
,26351927,volume of distribution,"The patients administered melatonin had a mean clearance, volume of distribution and absorption rate constant of melatonin was 55.2 L/h, 767 L and 0.76 h-1, respectively.",Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26351927/),l,767,154089,DB01065,Melatonin
,26351927,absorption rate constant,"The patients administered melatonin had a mean clearance, volume of distribution and absorption rate constant of melatonin was 55.2 L/h, 767 L and 0.76 h-1, respectively.",Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26351927/),1/[h],0.76,154090,DB01065,Melatonin
,31381847,Cmax,"The median Cmax was 4,690 pg/mL for CRA-melatonin and 23,352 pg/mL for IR-melatonin.","A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31381847/),[pg] / [ml],"4,690",156861,DB01065,Melatonin
,31381847,Cmax,"The median Cmax was 4,690 pg/mL for CRA-melatonin and 23,352 pg/mL for IR-melatonin.","A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31381847/),[pg] / [ml],"23,352",156862,DB01065,Melatonin
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],12.1,157653,DB01065,Melatonin
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],8,157654,DB01065,Melatonin
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],18,157655,DB01065,Melatonin
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],11,157656,DB01065,Melatonin
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],253,157657,DB01065,Melatonin
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],249,157658,DB01065,Melatonin
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],10,157659,DB01065,Melatonin
,8412502,apparent elimination half-life,"In the rat, 2-iodomelatonin was slowly metabolized in vivo; its apparent elimination half-life was about 60 minutes, much longer than that reported for melatonin.","Primary pharmaco-toxicological evaluation of 2-iodomelatonin, a potent melatonin agonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8412502/),min,60,161196,DB01065,Melatonin
,3171890,half-lives,"Computer analysis of plasma 14C-MT kinetics showed a three-compartment system with half-lives of 0.21 +/- 0.05, 5.97 +/- 1.11, and 47.52 +/- 8.86 min.","Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),min,0.21,162924,DB01065,Melatonin
,3171890,half-lives,"Computer analysis of plasma 14C-MT kinetics showed a three-compartment system with half-lives of 0.21 +/- 0.05, 5.97 +/- 1.11, and 47.52 +/- 8.86 min.","Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),min,5.97,162925,DB01065,Melatonin
,3171890,half-lives,"Computer analysis of plasma 14C-MT kinetics showed a three-compartment system with half-lives of 0.21 +/- 0.05, 5.97 +/- 1.11, and 47.52 +/- 8.86 min.","Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),min,47.52,162926,DB01065,Melatonin
,3171890,volume of distribution,"The volume of distribution and the clearance were 1,736 +/- 349 ml.kg-1 and 25.1 +/- 1.7 ml.min-1.kg-1 respectively.","Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),[ml] / [kg],"1,736",162927,DB01065,Melatonin
,3171890,clearance,"The volume of distribution and the clearance were 1,736 +/- 349 ml.kg-1 and 25.1 +/- 1.7 ml.min-1.kg-1 respectively.","Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),[ml] / [kg·min],25.1,162928,DB01065,Melatonin
,3171890,half-lives,The decay followed a two-compartment system with half-lives of 16.5 +/- 2.9 and 47.3 +/- 8.6 min.,"Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),min,16.5,162929,DB01065,Melatonin
,3171890,half-lives,The decay followed a two-compartment system with half-lives of 16.5 +/- 2.9 and 47.3 +/- 8.6 min.,"Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),min,47.3,162930,DB01065,Melatonin
,3171890,CSF/plasma concentration ratio,The CSF/plasma concentration ratio was 0.38 at the steady state (30 min).,"Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171890/),,0.38,162931,DB01065,Melatonin
,7550582,half-life,"Pharmacokinetic studies of exogenous melatonin (100 or 1 micrograms) administered to 5-methoxypsoralen (MOP)-treated rats, showed that MOP administration induced an increase in the half-life of melatonin from 22 to 67 min.",5-Methoxypsoralen inhibits 6-hydroxylation of melatonin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550582/),min,22,168686,DB01065,Melatonin
,7550582,half-life,"Pharmacokinetic studies of exogenous melatonin (100 or 1 micrograms) administered to 5-methoxypsoralen (MOP)-treated rats, showed that MOP administration induced an increase in the half-life of melatonin from 22 to 67 min.",5-Methoxypsoralen inhibits 6-hydroxylation of melatonin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550582/),min,67,168687,DB01065,Melatonin
,7297507,half-life,"Data from the tritiated melatonin experiments gave a half-life of 23 min, and data from the RIA experiments gave a half-life of 17 min.",The half-life of melatonin elimination from rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297507/),min,23,173099,DB01065,Melatonin
,7297507,half-life,"Data from the tritiated melatonin experiments gave a half-life of 23 min, and data from the RIA experiments gave a half-life of 17 min.",The half-life of melatonin elimination from rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297507/),min,17,173100,DB01065,Melatonin
,9062870,apparent elimination half-life,"The apparent elimination half-life of melatonin following an intravenous dose of 3 mg/kg (5 mg/kg in rats) was 19.8, 18.6, and 34.2 minutes, respectively, in rats, dogs, and monkeys.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),min,19.8,183220,DB01065,Melatonin
,9062870,apparent elimination half-life,"The apparent elimination half-life of melatonin following an intravenous dose of 3 mg/kg (5 mg/kg in rats) was 19.8, 18.6, and 34.2 minutes, respectively, in rats, dogs, and monkeys.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),min,18.6,183221,DB01065,Melatonin
,9062870,apparent elimination half-life,"The apparent elimination half-life of melatonin following an intravenous dose of 3 mg/kg (5 mg/kg in rats) was 19.8, 18.6, and 34.2 minutes, respectively, in rats, dogs, and monkeys.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),min,34.2,183222,DB01065,Melatonin
,9062870,dose normalized oral bioavailability,"The dose normalized oral bioavailability of melatonin following a 10 mg/kg oral dose was 53.5% in rats, while it was in excess of 100% in dogs and monkeys.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),%,53.5,183223,DB01065,Melatonin
excess of,9062870,dose normalized oral bioavailability,"The dose normalized oral bioavailability of melatonin following a 10 mg/kg oral dose was 53.5% in rats, while it was in excess of 100% in dogs and monkeys.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),%,100,183224,DB01065,Melatonin
,9062870,bioavailability,"Further, bioavailability of melatonin following a 10 mg/kg intraperitoneal administration in rats was 74.0%, suggesting the lack of substantial first-pass hepatic extraction of melatonin in rats.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),%,74.0,183225,DB01065,Melatonin
,9062870,oral bioavailability,"However, the oral bioavailability of melatonin in dogs decreased to 16.9% following a 1 mg/kg oral dose, indicating dose-dependent bioavailability in dogs.",Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062870/),%,16.9,183226,DB01065,Melatonin
,32178261,maximum concentration,Melatonin showed maximum concentration (45.4 pg/mL) 90 min after lentil sprout administration.,Bioavailability of Melatonin from Lentil Sprouts and Its Role in the Plasmatic Antioxidant Status in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32178261/),[pg] / [ml],45.4,184367,DB01065,Melatonin
,18423009,Nocturnal sleep time,"Nocturnal sleep time was 2.5 hours in the placebo group (mean SEI = 0.26, 95% confidence interval [CI] 0.17 to 0.36).",Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18423009/),h,2.5,186835,DB01065,Melatonin
,10535762,production rate,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[μg] / [kg·night],0.55,189701,DB01065,Melatonin
,10535762,production rate,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[μg] / [kg·night],0.26,189702,DB01065,Melatonin
,10535762,mass of melatonin released,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[pg] / [ml],275,189703,DB01065,Melatonin
,10535762,mass of melatonin released,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[pg] / [ml],145,189704,DB01065,Melatonin
,10535762,amplitude of secretory bursts,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[pg] / [min·ml],7.8,189705,DB01065,Melatonin
,10535762,amplitude of secretory bursts,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[pg] / [min·ml],4.7,189706,DB01065,Melatonin
,10535762,production rate,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[ng] / [ml·night],2.76,189707,DB01065,Melatonin
,10535762,production rate,"The estimated melatonin production rate from group 1 (0.55 +/- 0.21 microg/kg/night) was significantly higher than that of group 2 (0.26 +/- 0.19 microg/kg/night), as well as the mass of melatonin released per burst (275 +/- 110 vs. 145 +/- 130 pg/mL for groups 1 and 2, respectively), the amplitude of secretory bursts (7.8 +/- 3.2 vs. 4.7 +/- 3.5 pg/mL/min), and the pulsatile melatonin production rate (2.76 +/- 1.14 vs. 1.27 +/- 0.97 ng/mL/night).",Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10535762/),[ng] / [ml·night],1.27,189708,DB01065,Melatonin
,11038434,total body clearance,"After i.v. administration, the maximum plasma concentration (C(max)) and the area under the plasma concentration-time curve (AUC) values were significantly different in male and female subjects, but there was no significant gender difference in total body clearance normalized to body weight: 1.27+/-0.20 L/h/kg and 1.18+/-0.22 L/h/kg for males and females, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[l] / [h·kg],1.27,190794,DB01065,Melatonin
,11038434,total body clearance,"After i.v. administration, the maximum plasma concentration (C(max)) and the area under the plasma concentration-time curve (AUC) values were significantly different in male and female subjects, but there was no significant gender difference in total body clearance normalized to body weight: 1.27+/-0.20 L/h/kg and 1.18+/-0.22 L/h/kg for males and females, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[l] / [h·kg],1.18,190795,DB01065,Melatonin
,11038434,apparent terminal half-life (t(1/2(z))),"The apparent terminal half-life (t(1/2(z))) values were 36+/-2 and 41+/-10 min, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),min,36,190796,DB01065,Melatonin
,11038434,apparent terminal half-life (t(1/2(z))),"The apparent terminal half-life (t(1/2(z))) values were 36+/-2 and 41+/-10 min, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),min,41,190797,DB01065,Melatonin
,11038434,maximum plasma MLT concentration C(max),"The maximum plasma MLT concentration C(max)+/-S.D. was found at 243.7+/-124.6 pg/mL and 623.6+/-575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236+/-107 pg.h/mL and 701+/-645 pg.h/mL.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[pg] / [ml],243.7,190798,DB01065,Melatonin
,11038434,maximum plasma MLT concentration C(max),"The maximum plasma MLT concentration C(max)+/-S.D. was found at 243.7+/-124.6 pg/mL and 623.6+/-575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236+/-107 pg.h/mL and 701+/-645 pg.h/mL.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[pg] / [ml],623.6,190799,DB01065,Melatonin
,11038434,AUCs,"The maximum plasma MLT concentration C(max)+/-S.D. was found at 243.7+/-124.6 pg/mL and 623.6+/-575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236+/-107 pg.h/mL and 701+/-645 pg.h/mL.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[h·pg] / [ml],236,190800,DB01065,Melatonin
,11038434,AUCs,"The maximum plasma MLT concentration C(max)+/-S.D. was found at 243.7+/-124.6 pg/mL and 623.6+/-575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236+/-107 pg.h/mL and 701+/-645 pg.h/mL.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),[h·pg] / [ml],701,190801,DB01065,Melatonin
,11038434,absolute bioavailability,"The absolute bioavailability of MLT was from 1 to 37%: mean=8.6+/-3.9% and 16.8+/-12.7% for male and female subjects, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),%,1 to 37,190802,DB01065,Melatonin
,11038434,absolute bioavailability,"The absolute bioavailability of MLT was from 1 to 37%: mean=8.6+/-3.9% and 16.8+/-12.7% for male and female subjects, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),%,8.6,190803,DB01065,Melatonin
,11038434,absolute bioavailability,"The absolute bioavailability of MLT was from 1 to 37%: mean=8.6+/-3.9% and 16.8+/-12.7% for male and female subjects, respectively.",Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038434/),%,16.8,190804,DB01065,Melatonin
,17389558,clearance,"Ramelteon clearance was significantly reduced in elderly vs young volunteers (384 vs 883 mL/min/kg, P<.01) and half-life significantly increased (1.9 vs 1.3 h, P<.001).","Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389558/),[ml] / [kg·min],384,192469,DB01065,Melatonin
,17389558,clearance,"Ramelteon clearance was significantly reduced in elderly vs young volunteers (384 vs 883 mL/min/kg, P<.01) and half-life significantly increased (1.9 vs 1.3 h, P<.001).","Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389558/),[ml] / [kg·min],883,192470,DB01065,Melatonin
,17389558,half-life,"Ramelteon clearance was significantly reduced in elderly vs young volunteers (384 vs 883 mL/min/kg, P<.01) and half-life significantly increased (1.9 vs 1.3 h, P<.001).","Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389558/),h,1.9,192471,DB01065,Melatonin
,17389558,half-life,"Ramelteon clearance was significantly reduced in elderly vs young volunteers (384 vs 883 mL/min/kg, P<.01) and half-life significantly increased (1.9 vs 1.3 h, P<.001).","Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389558/),h,1.3,192472,DB01065,Melatonin
,8894592,Plasma protein binding,"Plasma protein binding of melatonin was approximately 33%, irrespective of group or sampling time.",Pharmacokinetically guided melatonin scheduling in rats with circadian system suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894592/),%,33,194020,DB01065,Melatonin
,24650045,elimination half-life,Melatonin was rapidly cleared at all doses with a median [range] elimination half-life of 51.7 [29.5-63.2] min across all doses.,Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650045/),min,51.7,200101,DB01065,Melatonin
,30625289,Tmax,PK analysis of melatonin revealed Tmax at 5 min with closely spaced another distinct concentration peak at 20 min.,PK-PD based optimal dose and time for orally administered supra-pharmacological dose of melatonin to prevent radiation induced mortality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30625289/),min,5,200613,DB01065,Melatonin
,30625289,DRGP,"DRGP for melatonin was thus 45 min, while optimal oral dose ranged from 125 to 250 mg/kg.",PK-PD based optimal dose and time for orally administered supra-pharmacological dose of melatonin to prevent radiation induced mortality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30625289/),min,45,200614,DB01065,Melatonin
,18982259,MT contents,"The MT contents in 20% coated sugar spheres of three batches (B1, B2 and B3) were 3.3+/-0.08, 2.4+/-0.1 and 2.5+/-0.13 mg per gram of coated sugar spheres, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),[mg] / [gram],3.3,201294,DB01065,Melatonin
,18982259,MT contents,"The MT contents in 20% coated sugar spheres of three batches (B1, B2 and B3) were 3.3+/-0.08, 2.4+/-0.1 and 2.5+/-0.13 mg per gram of coated sugar spheres, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),[mg] / [gram],2.4,201295,DB01065,Melatonin
,18982259,MT contents,"The MT contents in 20% coated sugar spheres of three batches (B1, B2 and B3) were 3.3+/-0.08, 2.4+/-0.1 and 2.5+/-0.13 mg per gram of coated sugar spheres, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),[mg] / [gram],2.5,201296,DB01065,Melatonin
,18982259,release half-lives (T(50%)),"However, the release half-lives (T(50%)) of MT from B1, B2 and B3 was 3.70+/-0.2, 5.2+/-0.2 and 4.9+/-0.07h, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),h,3.70,201297,DB01065,Melatonin
,18982259,release half-lives (T(50%)),"However, the release half-lives (T(50%)) of MT from B1, B2 and B3 was 3.70+/-0.2, 5.2+/-0.2 and 4.9+/-0.07h, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),h,5.2,201298,DB01065,Melatonin
,18982259,release half-lives (T(50%)),"However, the release half-lives (T(50%)) of MT from B1, B2 and B3 was 3.70+/-0.2, 5.2+/-0.2 and 4.9+/-0.07h, respectively.",Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18982259/),h,4.9,201299,DB01065,Melatonin
,27566320,t ½ absorption,"Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively.",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,10.8,206950,DB01065,Melatonin
,27566320,t ½ absorption,"Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively.",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,9.5,206951,DB01065,Melatonin
,27566320,T max,"Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively.",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,90.0,206952,DB01065,Melatonin
,27566320,T max,"Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively.",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,9.5,206953,DB01065,Melatonin
,27566320,T max,"Median (interquartile range) values of t ½ absorption and T max were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively.",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,30.0,206954,DB01065,Melatonin
,27566320,C max,"C max values were significantly higher during surgery [5497.5 (2077.1-13,233.8) pg/ml] compared with postoperative values [2340.5 (1672.4-8871.4) pg/ml] (p = 0.005).",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),[pg] / [ml],5497.5,206955,DB01065,Melatonin
,27566320,C max,"C max values were significantly higher during surgery [5497.5 (2077.1-13,233.8) pg/ml] compared with postoperative values [2340.5 (1672.4-8871.4) pg/ml] (p = 0.005).",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),[pg] / [ml],2340.5,206956,DB01065,Melatonin
,27566320,t ½ elimination,"Correspondingly, t ½ elimination was significantly extended during the postoperative phase [103.5 (57.8-237.8) min] compared with the perioperative phase [60.5 (47.8-83.6) min] (p = 0.015).",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,103.5,206957,DB01065,Melatonin
,27566320,t ½ elimination,"Correspondingly, t ½ elimination was significantly extended during the postoperative phase [103.5 (57.8-237.8) min] compared with the perioperative phase [60.5 (47.8-83.6) min] (p = 0.015).",Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27566320/),min,60.5,206958,DB01065,Melatonin
,26579365,zero order release rates,"The in vivo release of MT deduced from the healthy younger population physiological MT profiles as the pharmacokinetic output of the bio-mimetic DDS showed a two-phase profile with two different zero order release rates, namely, 4.919 μg/h during 0-4 h (r=0.9992), and 11.097 μg/h during 4-12 h (r=0.9886), respectively.",Bio-mimetic drug delivery systems designed to help the senior population reconstruct melatonin plasma profiles similar to those of the healthy younger population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579365/),[μg] / [h],4.919,208336,DB01065,Melatonin
,26579365,zero order release rates,"The in vivo release of MT deduced from the healthy younger population physiological MT profiles as the pharmacokinetic output of the bio-mimetic DDS showed a two-phase profile with two different zero order release rates, namely, 4.919 μg/h during 0-4 h (r=0.9992), and 11.097 μg/h during 4-12 h (r=0.9886), respectively.",Bio-mimetic drug delivery systems designed to help the senior population reconstruct melatonin plasma profiles similar to those of the healthy younger population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579365/),[μg] / [h],11.097,208337,DB01065,Melatonin
>,26579365,similarity factor f 2,"The high similarity between the experimental drug release profiles and the theoretical profiles (similarity factor f 2>50) and the high correlation between the predicted plasma concentration profiles and the theoretical plasma concentration profiles (r=0.9366, 0.9163, 0.9264) indicated that a prototype bio-mimetic drug delivery system of MT was established.",Bio-mimetic drug delivery systems designed to help the senior population reconstruct melatonin plasma profiles similar to those of the healthy younger population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579365/),,50,208338,DB01065,Melatonin
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[ml] / [h],72.1,214088,DB01065,Melatonin
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [ml],"101,163",214089,DB01065,Melatonin
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,15,214090,DB01065,Melatonin
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,210,214091,DB01065,Melatonin
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,28,214092,DB01065,Melatonin
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,126,214093,DB01065,Melatonin
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],5400,214094,DB01065,Melatonin
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],6.56 × 10(10),214095,DB01065,Melatonin
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],0.97,214096,DB01065,Melatonin
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],132.50,214097,DB01065,Melatonin
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,35,214098,DB01065,Melatonin
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,1602,214099,DB01065,Melatonin
,26008214,Bioavailability,Bioavailability of oral melatonin ranged from 9 to 33%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,9 to 33,214100,DB01065,Melatonin
,26008214,Tmax,"Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin.",Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,50,214101,DB01065,Melatonin
,26008214,T1/2,T1/2 was 45 min in both administration routes.,Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,45,214102,DB01065,Melatonin
,26008214,Bioavailability,Bioavailability of oral melatonin was approximately 15%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,15,214103,DB01065,Melatonin
,18314560,peak endogenous melatonin concentrations,The younger subjects had significantly higher peak endogenous melatonin concentrations (+/- SD) and greater inter-individual variability (100.9 +/- 48.6 pg/ml) than the older subjects (34.5 +/- 15.4 pg/ml).,Endogenous melatonin levels and the fate of exogenous melatonin: age effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18314560/),[pg] / [ml],100.9,219829,DB01065,Melatonin
,18314560,peak endogenous melatonin concentrations,The younger subjects had significantly higher peak endogenous melatonin concentrations (+/- SD) and greater inter-individual variability (100.9 +/- 48.6 pg/ml) than the older subjects (34.5 +/- 15.4 pg/ml).,Endogenous melatonin levels and the fate of exogenous melatonin: age effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18314560/),[pg] / [ml],34.5,219830,DB01065,Melatonin
,9124558,clearance half-life,"The estimated parameters [median (range)] were clearance half-life of 23.67 (14.79-59.93) min, synthesis onset time of 2206 (1940-0029), synthesis offset time of 0621 (0246-0817), and maximum N-acetyltransferase activity of 7.17(2.34-17.93) pmol x l(-1) x min(-1).",A mathematical model of diurnal variations in human plasma melatonin levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124558/),min,23.67,224693,DB01065,Melatonin
,9124558,maximum N-acetyltransferase activity,"The estimated parameters [median (range)] were clearance half-life of 23.67 (14.79-59.93) min, synthesis onset time of 2206 (1940-0029), synthesis offset time of 0621 (0246-0817), and maximum N-acetyltransferase activity of 7.17(2.34-17.93) pmol x l(-1) x min(-1).",A mathematical model of diurnal variations in human plasma melatonin levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124558/),[pM] / [l·min],7.17,224694,DB01065,Melatonin
,18603221,elimination half-life,"It is a melatonin 1/2 receptor agonist with rapid absorption, extensive first-pass metabolism and an elimination half-life of just over 1h.",Efficacy and clinical safety of ramelteon: an evidence-based review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18603221/),h,1,224723,DB01065,Melatonin
,6493445,absorption constant (ka),Changes in serum melatonin levels were best described by a biexponential equation with an absorption constant (ka) of 1.72 h-1 (half-life = 0.40 h) and an elimination constant (ke1) of 0.87 h-1 (half-life = 0.80 h).,Bioavailability of oral melatonin in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6493445/),1/[h],1.72,226471,DB01065,Melatonin
,6493445,half-life,Changes in serum melatonin levels were best described by a biexponential equation with an absorption constant (ka) of 1.72 h-1 (half-life = 0.40 h) and an elimination constant (ke1) of 0.87 h-1 (half-life = 0.80 h).,Bioavailability of oral melatonin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6493445/),h,0.40,226472,DB01065,Melatonin
,6493445,elimination constant (ke1),Changes in serum melatonin levels were best described by a biexponential equation with an absorption constant (ka) of 1.72 h-1 (half-life = 0.40 h) and an elimination constant (ke1) of 0.87 h-1 (half-life = 0.80 h).,Bioavailability of oral melatonin in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6493445/),1/[h],0.87,226473,DB01065,Melatonin
,6493445,half-life,Changes in serum melatonin levels were best described by a biexponential equation with an absorption constant (ka) of 1.72 h-1 (half-life = 0.40 h) and an elimination constant (ke1) of 0.87 h-1 (half-life = 0.80 h).,Bioavailability of oral melatonin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6493445/),h,0.80,226474,DB01065,Melatonin
,15302228,Tmax,Pharmacokinetic analysis showed a consistent Tmax across all doses with a mean of 1.12 +/- 0.11 hr for all groups (mean +/- SD).,"A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),h,1.12,236315,DB01065,Melatonin
,15302228,half-life,"The half-life was also consistent across dose, with a mean of 1.04 +/- 0.04 hr.","A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),h,1.04,236316,DB01065,Melatonin
,15302228,Maximum plasma concentrations,"Maximum plasma concentrations increased with increasing dose with values of 44.83 +/- 29.79, 100.3 +/- 41.08, 79.84 +/- 26.36 and 410.3 +/- 129.4 ng/ml at doses of 20, 35, 50 and 100 mg, respectively.","A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),[ng] / [ml],44.83,236317,DB01065,Melatonin
,15302228,Maximum plasma concentrations,"Maximum plasma concentrations increased with increasing dose with values of 44.83 +/- 29.79, 100.3 +/- 41.08, 79.84 +/- 26.36 and 410.3 +/- 129.4 ng/ml at doses of 20, 35, 50 and 100 mg, respectively.","A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),[ng] / [ml],100.3,236318,DB01065,Melatonin
,15302228,Maximum plasma concentrations,"Maximum plasma concentrations increased with increasing dose with values of 44.83 +/- 29.79, 100.3 +/- 41.08, 79.84 +/- 26.36 and 410.3 +/- 129.4 ng/ml at doses of 20, 35, 50 and 100 mg, respectively.","A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),[ng] / [ml],79.84,236319,DB01065,Melatonin
,15302228,Maximum plasma concentrations,"Maximum plasma concentrations increased with increasing dose with values of 44.83 +/- 29.79, 100.3 +/- 41.08, 79.84 +/- 26.36 and 410.3 +/- 129.4 ng/ml at doses of 20, 35, 50 and 100 mg, respectively.","A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302228/),[ng] / [ml],410.3,236320,DB01065,Melatonin
,8106960,plasma clearances,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),[l] / [kg·min],0.0267,236822,DB01065,Melatonin
,8106960,plasma clearances,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),[l] / [kg·min],0.0229,236823,DB01065,Melatonin
,8106960,steady state volume of distribution,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),[l] / [kg],0.826,236824,DB01065,Melatonin
,8106960,steady state volume of distribution,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),[l] / [kg],0.780,236825,DB01065,Melatonin
,8106960,terminal half lives,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),min,58.9,236826,DB01065,Melatonin
,8106960,terminal half lives,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),min,64.1,236827,DB01065,Melatonin
,8106960,mean residence times,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),min,32.0,236828,DB01065,Melatonin
,8106960,mean residence times,"The mean (+/- SD) kinetic parameters describing melatonin disposition, during day and night, respectively, were plasma clearances: 0.0267 +/- 0.0084 l/kg per min and 0.0229 +/- 0.0031 l/kg per min; steady state volume of distribution: 0.826 +/- 0.229 l/kg and 0.780 +/- 0.193 l/kg; terminal half lives: 58.9 +/- 23.7 min and 64.1 +/- 33.7 min; mean residence times: 32.0 +/- 8.8 min and 33.9 +/- 6.2 min.",Absence of circadian rhythm in the disposition of melatonin in the cow. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106960/),min,33.9,236829,DB01065,Melatonin
,10354964,AUCs,"The mean AUCs of endogenous melatonin before the two treatment days were 248 and 234 pg.h/mL, respectively.",Feasibility and functionality of OROS melatonin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354964/),[h·pg] / [ml],248,250652,DB01065,Melatonin
,10354964,AUCs,"The mean AUCs of endogenous melatonin before the two treatment days were 248 and 234 pg.h/mL, respectively.",Feasibility and functionality of OROS melatonin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354964/),[h·pg] / [ml],234,250653,DB01065,Melatonin
,10354964,AUCs,"Serum concentrations of melatonin corrected for endogenous production increased proportionally with dose, with AUCs of 288 and 1069 pg.h/mL, respectively.",Feasibility and functionality of OROS melatonin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354964/),[h·pg] / [ml],288,250654,DB01065,Melatonin
,10354964,AUCs,"Serum concentrations of melatonin corrected for endogenous production increased proportionally with dose, with AUCs of 288 and 1069 pg.h/mL, respectively.",Feasibility and functionality of OROS melatonin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354964/),[h·pg] / [ml],1069,250655,DB01065,Melatonin
,11120654,rate of secretion,"By use of the MLT clearance given by pharmacokinetics, the amount of secreted MLT was found to be 35.7 and 21.6 microg for men and women, respectively, and the rate of secretion was 4.6 and 2.8 microg/h, respectively.",Melatonin secretion occurs at a constant rate in both young and older men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120654/),[μg] / [h],4.6,252073,DB01065,Melatonin
,11120654,rate of secretion,"By use of the MLT clearance given by pharmacokinetics, the amount of secreted MLT was found to be 35.7 and 21.6 microg for men and women, respectively, and the rate of secretion was 4.6 and 2.8 microg/h, respectively.",Melatonin secretion occurs at a constant rate in both young and older men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120654/),[μg] / [h],2.8,252074,DB01065,Melatonin
,11120654,duration of secretion,"No significant gender difference was observed for onset times of secretion or duration of secretion (7.6-8.6 h) within the two groups, or between young and older subjects.",Melatonin secretion occurs at a constant rate in both young and older men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120654/),h,7.6-8.6,252075,DB01065,Melatonin
,26440286,flow rate,Acetonitrile and 5 mM ammonium acetate were used as the mobile phase with a gradient elution at a flow rate of 0.2 mL/min.,"A novel LC-MS/MS assay for the simultaneous determination of melatonin and its two major metabolites, 6-hydroxymelatonin and 6-sulfatoxymelatonin in dog plasma: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440286/),[ml] / [min],0.2,252988,DB01065,Melatonin
,26440286,analytical run time,The analytical run time of 6.5 min was divided into two periods according to ionization mode.,"A novel LC-MS/MS assay for the simultaneous determination of melatonin and its two major metabolites, 6-hydroxymelatonin and 6-sulfatoxymelatonin in dog plasma: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440286/),min,6.5,252989,DB01065,Melatonin
,25728168,flow rate,"The plasma sample was treated by a liquid-liquid extraction and separated on a kromasil C18 column at an isocratic flow rate of 0.3 mL/min using methanol and 0.1% formic acid in water (75:25, v/v) as mobile phase.",A validated sensitive HPLC-MS/MS method for quantification of a potential hypnotic drug MT502 and its application to a pharmacokinetic study in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728168/),[ml] / [min],0.3,253493,DB01065,Melatonin
,657540,recovery,The recovery of melatonin added to calf serum is 96%.,A simplified radioimmunoassay for melatonin and its application to biological fluids. Preliminary observations on the half-life of plasma melatonin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657540/),%,96,256348,DB01065,Melatonin
,657540,peak value,"The peak value, 620 nmol/l, was noted after 0.5 h and the melatonin concentration was still above the normal range at 24 h (2.1 nmol/l).",A simplified radioimmunoassay for melatonin and its application to biological fluids. Preliminary observations on the half-life of plasma melatonin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657540/),[nM] / [l],620,256349,DB01065,Melatonin
,8836952,plasma half-lives,"Elimination for all dose levels was rapid, with mean plasma half-lives between 33 and 47 min.",The hypothermic effect of melatonin on core body temperature: is more better? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836952/),min,33 and 47,259571,DB01065,Melatonin
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],2.47,263208,DB01065,Melatonin
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],3.17,263209,DB01065,Melatonin
,10883420,absolute bioavailability,Both the 2 and the 4 mg oral dosages showed an absolute bioavailability of approximately 15%.,The absolute bioavailability of oral melatonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883420/),%,15,263784,DB01065,Melatonin
,16432265,C(max),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[ng] / [ml],1.15,264463,DB01065,Melatonin
,16432265,C(max),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[ng] / [ml],5.73,264464,DB01065,Melatonin
,16432265,C(max),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[ng] / [ml],6.92,264465,DB01065,Melatonin
,16432265,C(max),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[ng] / [ml],17.4,264466,DB01065,Melatonin
,16432265,C(max),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[ng] / [ml],25.9,264467,DB01065,Melatonin
,16432265,AUC(infinity),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[h·n] / [ml],1.71,264468,DB01065,Melatonin
,16432265,AUC(infinity),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[h·n] / [ml],6.95,264469,DB01065,Melatonin
,16432265,AUC(infinity),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[h·n] / [ml],9.88,264470,DB01065,Melatonin
,16432265,AUC(infinity),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[h·n] / [ml],22.5,264471,DB01065,Melatonin
,16432265,AUC(infinity),"C(max) and AUC(infinity) (mean [%CV]) increased with each dose: C(max) = 1.15 (109), 5.73 (97), 6.92 (77), 17.4 (76), and 25.9 (77) ng/mL, respectively, and AUC(infinity) = 1.71 (114), 6.95 (108), 9.88 (78), 22.5 (80), and 36.1 (71 n x h/mL), respectively.","Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),[h·n] / [ml],36.1,264472,DB01065,Melatonin
,16432265,T(max),Mean T(max) values of 0.75 to 0.94 hours and mean elimination half-life of 0.83 to 1.90 hours remained relatively constant.,"Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),h,0.75 to 0.94,264473,DB01065,Melatonin
,16432265,elimination half-life,Mean T(max) values of 0.75 to 0.94 hours and mean elimination half-life of 0.83 to 1.90 hours remained relatively constant.,"Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432265/),h,0.83 to 1.90,264474,DB01065,Melatonin
,4055987,production,"Normal melatonin production was 28.8 micrograms/day, while the production rate for cirrhotic patients was 12.3 micrograms/day.",Pharmacokinetics of melatonin in man: first pass hepatic metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055987/),[μg] / [d],28.8,269151,DB01065,Melatonin
,4055987,production rate,"Normal melatonin production was 28.8 micrograms/day, while the production rate for cirrhotic patients was 12.3 micrograms/day.",Pharmacokinetics of melatonin in man: first pass hepatic metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055987/),[μg] / [d],12.3,269152,DB01065,Melatonin
,21709095,total body clearance,Melatonin altered colistin pharmacokinetics; the total body clearance in the colistin-melatonin group (1.82 ± 0.26 ml/min/kg) was lower than in the colistin group (4.28 ± 0.93 ml/min/kg).,Melatonin attenuates colistin-induced nephrotoxicity in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709095/),[ml] / [kg·min],1.82,269206,DB01065,Melatonin
,21709095,total body clearance,Melatonin altered colistin pharmacokinetics; the total body clearance in the colistin-melatonin group (1.82 ± 0.26 ml/min/kg) was lower than in the colistin group (4.28 ± 0.93 ml/min/kg).,Melatonin attenuates colistin-induced nephrotoxicity in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709095/),[ml] / [kg·min],4.28,269207,DB01065,Melatonin
